ArticleScientific reports2018
Upregulation of SOX2-activated lncRNA ANRIL promotes nasopharyngeal carcinoma cell growth.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- LncRNA-ANRIL regulates CDKN2A to promote malignant proliferation of Kasumi-1 cells.Cell division · 2025Article
- The Long Non-Coding RNA ANRIL in Cancers.Cancers · 2023Review
- Silencing of lncRNA MIR31HG promotes nasopharyngeal carcinoma cell proliferation and inhibits apoptosis through suppressing the PI3K/AKT signaling pathway.Journal of clinical laboratory analysis · 2022Article
- KTN1-AS1, a SOX2-mediated lncRNA, activates epithelial-mesenchymal transition process in esophageal squamous cell carcinoma.Scientific reports · 2022Article
- Emerging roles of lncRNA in Nasopharyngeal Carcinoma and therapeutic opportunities.International journal of biological sciences · 2022Review
- Differential non-coding RNAs expression profiles of invasive and non-invasive pituitary adenomas.Non-coding RNA research · 2021Article
- Long non-coding RNAs regulating multiple proliferative pathways in cancer cell.Translational cancer research · 2021Review
- The Role of Noncoding RNAs in the Regulation of Anoikis and Anchorage-Independent Growth in Cancer.International journal of molecular sciences · 2021Review
- LncRNA SNHG16 Facilitates Nasopharyngeal Carcinoma Progression by Acting as ceRNA to Sponge miR-520a-3p and Upregulate MAPK1 Expression.Cancer management and research · 2021Article
- Emerging Roles for theBiomolecules · 2020Review
- Diagnostic and Prognostic Indications of Nasopharyngeal Carcinoma.Diagnostics (Basel, Switzerland) · 2020Review
- The Long Non-Coding RNACancers · 2020Article
- LINC00667 Sponges miR-4319 to Promote the Development of Nasopharyngeal Carcinoma by Increasing FOXQ1 Expression.Frontiers in oncology · 2020Article
- LncRNAOncoTargets and therapy · 2020Article
- Tumor suppressor and oncogenic role of long non-coding RNAs in cancer.Northern clinics of Istanbul · 2020Review
- Long noncoding RNA ZFAS1 promotes tumorigenesis and metastasis in nasopharyngeal carcinoma by sponging miR-892b to up-regulate LPAR1 expression.Journal of cellular and molecular medicine · 2020Article
- LINC01116 accelerates nasopharyngeal carcinoma progression based on its enhancement on MYC transcription activity.Cancer medicine · 2020Article
- MicroRNA-505, Suppressed by Oncogenic Long Non-coding RNA LINC01448, Acts as a Novel Suppressor of Glycolysis and Tumor Progression Through Inhibiting HK2 Expression in Pancreatic Cancer.Frontiers in cell and developmental biology · 2020Article
- Long noncoding RNA SMAD5-AS1 acts as a microRNA-106a-5p sponge to promote epithelial mesenchymal transition in nasopharyngeal carcinoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- High Positive Correlations betweenNon-coding RNA · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent molecularly targeted approaches have gained advances in nasopharyngeal carcinoma treatment. However, the estimated five-year survival rate has not met the desired degree of improvement. Here, we report that upregulation of the expression of the SOX2-activated lncRNA ANRIL is involved in nasopharyngeal carcinoma. ANRIL has been found to be upregulated in clinical nasopharyngeal carcinoma. Using genetic approaches targeting ANRIL in nasopharyngeal carcinoma cells, we found that the knockdown of ANRIL inhibits cell proliferation in vitro and in vivo. Mechanistically, SOX2 binds with ANRIL and increases its RNA level, which upregulates β-catenin signalling, resulting in enhanced nasopharyngeal carcinoma tumourigenesis. Expression levels of ANRIL are positively correlated with SOX2 and β-catenin in clinical nasopharyngeal carcinoma samples. Our findings demonstrate that the SOX2-ANRIL-β-catenin axis plays a critical role in nasopharyngeal carcinoma proliferation and provide a potential therapeutic approach for nasopharyngeal carcinoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.